Every round on record, with the sources behind each and the investors on them.
Multiply Labs develops robotic systems that automate manual steps in biologics manufacturing, making advanced therapies more accessible.
multiplylabs.comLinkedInSan FranciscoBiotechYC S16Founded 201679 people
8 sources · checked 2 times, last 6m ago
Business Insider names NantWorks alone as lead; the company release and another report name Dr. Patrick Soon-Shiong with NantWorks, so the company release's wording is used.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $75M $100M to date | 2026-10-06 | NantWorks, Patrick Soon-Shiong | 5 outlets. #36 in Trending |
8 sources · checked 2 times, last 6m ago [ VERIFIED ] read against 4 of 8 sources Business Insider names NantWorks alone as lead; the company release and another report name Dr. Patrick Soon-Shiong with NantWorks, so the company release's wording is used. | ||||
Multiply Labs builds robotic clusters that automate cell and gene therapy manufacturing for pharmaceutical and biotech companies.
LinkedIn via Alexandria from ycombinator.com
Manual manufacturing of advanced cell therapies is labor-intensive, expensive, slow, and vulnerable to contamination, while the company says its enclosed robotic systems can automate those steps and make therapies more accessible. The $75 million Series B brings total funding to more than $100 million and is intended to expand manufacturing capacity, product development, and engineering, regulatory, and commercial teams as Multiply Labs moves from clinical-stage deployments toward commercial production.
Checked against 10 sources today
Via Alexandria from FullEnrich: type, industry
Also named as backers in company research: MIT Sandbox Innovation Fund Program, Y Combinator, Pathfinder, Garage Capital, Dr. Patrick Soon-Shiong